FdaApplication

ANDA 209063

Back to search

Identifiers

Properties

PropertyValue
applicant_nameBRECKENRIDGE PHARMACEUTICAL INC
application_typeANDA
approval_date2019-11-26

Products (3)

ProductActive ingredientStrengthDosage form
RIVASTIGMINERIVASTIGMINE9.5MG/24HRFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINERIVASTIGMINE13.3MG/24HRFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINERIVASTIGMINE4.6MG/24HRFILM, EXTENDED RELEASE;TRANSDERMAL

3 products